With a revenue increase of 9.93% in the second quarter 2026, year on year to cumulative value of $3,117 million, Amneal Pharmaceuticals Inc 's revenue per employee grew on a trailing twelve months basis to $ 366,762, this marks a new company high. Within the Healthcare sector Employees of 272 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 2198, from total ranking in previous quarter at 2482. Amneal Pharmaceuticals Inc has 8,500 employees.
Approval of BORUZU: A Game-Changer in Bortezomib Administration Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited have jointly announced the U.S. Food and Drug Administration (FDA) approval of BORUZU, marking a significant advancement in the treatment landscape for patients requiring bortezomib therapy. BORUZU is noted as the first ready-to-use formulation of bortezomib, designed for both subcutaneous and intravenous (IV) administration.Bortezomib, a proteasome inhibitor, has been a cornerstone in the treatment of various hematologic malignancies, including multiple myeloma and certain types of lymphoma. Traditionally, the preparation of bortezomib for administration involves complex compounding procedures that demand skilled handling and adherence to strict protocols to ensure safety and efficacy. The introduction of BORUZU addresses these challenges by eliminating the need for such compounding, thereby simplifying the preparation process for healthcare providers.
BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has achieved a significant milestone that promises to enhance clinical practices in the administration of anesthesia. The U.S. Food and Drug Administration (FDA) has granted Abbreviated New Drug Application (ANDA) approval for Amneal s Propofol Injectable Emulsion USP, available in three concentrations: 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL) single-dose vials.Propofol, an intravenous drug, has long been a cornerstone in hospital settings for the induction and maintenance of anesthesia and sedation. The approval of these single-dose vials marks a strategic advancement in ensuring streamlined, efficient, and safe pharmacological interventions for patients undergoing various medical procedures.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
